Premier Alternatives

Kano Therapeutics

Biotechnology · Cambridge, MA · Founded 2021 · Privately Held (backing)

Developer of a biotechnological production platform intended to expand the reach of genome-editing-based therapies through the development of transformational biomaterials. Kano Therapeutics is based in Cambridge, MA and was founded in 2021. It was valued at $15 million at its seed round in Aug 2024, the last priced event on record. It has raised $7.4 million across 2 recorded rounds; the latest was a $5 million seed round in Aug 2024.

PMV mark · valuation
$15.0M
Oct 2026
Priced at
its seed round
Aug 2024
Total raised
$7.4M
Last round
Seed Round
Aug 2024

Kano Therapeutics key facts

as of Oct 2026
  • Developer of a biotechnological production platform intended to expand the reach of genome-editing-based therapies through the development of transformational biomaterials.
  • Kano Therapeutics is valued at approximately $15.0M as of Oct 2026, set at its seed round, Aug 2024; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $7.4M across 2 recorded rounds; the latest was Seed Round ($5.0M) in Aug 2024.
  • Notable investors include Metaplanet Holdings, Activate Global, Engine Ventures, ZAKA VC, VSquared Ventures — 12 tracked in total.
  • Kano Therapeutics has filed 1 Form D with the SEC, most recently May 2024 ($5.0M sold to 4 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$15.0M

Valued at $15.0M at its seed round, Aug 2024. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Kano Therapeutics with a free account
  • ·The complete investor list: 12 names
  • ·Watch Kano Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Kano Therapeutics funding rounds

2 rounds
Aug 2024Seed Round$5.0M▮
May 2022Seed Round$2.1M▮
Full funding history →

Kano Therapeutics valuation

Kano Therapeutics was valued at $15 million at its seed round in Aug 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Kano Therapeutics raised?

Kano Therapeutics has raised $7.4 million across 2 recorded rounds since 2022. The largest was a $5 million seed round in Aug 2024.

Kano Therapeutics has filed 1 Form D with the SEC, most recently in May 2024 ($5 million sold to 4 investors).

Kano Therapeutics investors

12 investors are on record for Kano Therapeutics, including Metaplanet Holdings, Activate Global, Engine Ventures and ZAKA VC. By type, the record holds 4 venture capital firms and 1 angel investor. The seed round in Aug 2024 drew 4 investors.

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: Azalea Therapeutics ($153 million), KaloCyte ($24.7 million) and Industrial Microbes ($24 million).

About Kano Therapeutics

Developer of a biotechnological production platform intended to expand the reach of genome-editing-based therapies through the development of transformational biomaterials. The company uses DNA nanotechnology and synthetic biology to design and engineer novel gene vectors that carry genetic information, providing pharmaceutical and synthetic biology companies with gene delivery and vaccine construct knowledge.

Industry
Biotechnology
Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2021
Employees
9
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.